Management of Stable COPD: An Update
Alexandru Corlateanu, Gloria Montanari, Alexandros G. Mathioudakis, Victor Botnaru and Nikolaos Siafakas
Affiliation: State University of Medicine and Pharmacy “Nicolae Testemitanu”, Stefan cel Mare street 165, 2004 Chisinau, Republic of Moldova.
Chronic Obstructive Pulmonary Disease (COPD), being a major cause of morbidity and mortality worldwide, is
a major problem for public health. It is predicted that its burden will continuously expand over the next years. This article
is an up-to-date review of both non-pharmacologic and pharmacologic management of COPD, which is now based on
new staging systems, able to predict prognosis and the response to different treatment approaches. Non-pharmacologic
therapies, such as smoking cessation, vaccinations and pulmonary rehabilitation are covered briefly. Current
pharmacologic management covers short acting beta-agonists (SABA), short acting muscarinic antagonists (SAMA), long
acting beta agonists (LABA), long acting antimuscarinics (LAMA), inhaled corticosteroids (ICS), LABA/ICS
combinations, xanthines, specific phosphodiesterase 4 (PDE4) inhibitors and oxygen therapy.
Keywords: Chronic obstructive pulmonary disease (COPD), disease management, pharmacotherapy, phenotypes,
Rights & PermissionsPrintExport